Q: Considering all the death crosses in their chart, it looks like Biosyent is in a condition where the technical indicators will rule the fundamentals for a bit. I bought it at the top end in an RRSP and TFSA (3%)so is it worth holding. Was the stock just stretched out too far in Q1 or are there some fundamental concerns? I don't have any issue holding on for a couple of quarters or buying a bit more when it bottoms if there are no serious fundamental concerns.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hello,
Since Jason Donville recommended Biosyent (RX) on December 24 I was in on what I perceived was a dip and luckily out again before it dipped another big chunk. Similar thing with Knight (GUD).
My question is whether there is a price point at which either of these become "no brainer" buys? For an investor willing to absorb some risk are we near that point with each stock at $7?
Since Jason Donville recommended Biosyent (RX) on December 24 I was in on what I perceived was a dip and luckily out again before it dipped another big chunk. Similar thing with Knight (GUD).
My question is whether there is a price point at which either of these become "no brainer" buys? For an investor willing to absorb some risk are we near that point with each stock at $7?
Q: After being a top pick of Jason Donville on Dec 24/14,RX's price increased to $12.08 on Dec 31,but it had steadily & sharply declined to $7.57 on May 14 despite 2 good quarterly reports @ end of Feb & May 13.I am really confused.I bought a small amount @ $10. Please advise if this is a Hold,Sell or average down,Thanks for your normal great opinions & services
Q: Guys,
Great service, I've only been a subscriber for a few days but have got more out of this then any other newsletter/board I've ever found. My question is on Biosyent- within the past week a second analyst has began covering the stock and has in my opinion very low EPS/Revenue estimates for 2016. Do you know who recently picked up coverage and what reasons they gave for estimates significantly below Cantor's? Thank you!
Great service, I've only been a subscriber for a few days but have got more out of this then any other newsletter/board I've ever found. My question is on Biosyent- within the past week a second analyst has began covering the stock and has in my opinion very low EPS/Revenue estimates for 2016. Do you know who recently picked up coverage and what reasons they gave for estimates significantly below Cantor's? Thank you!
Q: Yesterday, a member asked if we could see any news about RX.V. The company "advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price". Source: http://www.stockhouse.com/news/press-releases/2015/04/10/biosyent-comments-on-recent-market-activity. The stock is now up 9%.
Q: What in the devil is happening with Biosyent? I don't see any news on it but it continues to go down. Is it time to buy more or just hold off until something tells us maybe we should be selling?
Q: Hi, I've been watching RX since it was about 11 dollars, hoping for an opportunity to get in. It has recently taken quite a dive to 8 dollars and looks like it might go down further. Has something changed with the company or would this be a good time to buy?
SYZ is doing the same thing. Is this a good time to get in or will it drop further?
Thanks!
SYZ is doing the same thing. Is this a good time to get in or will it drop further?
Thanks!
Q: Any reason to be concerned with this stock? Pulling back quite a bit in the past week. Would you be a buyer, seller or would you hold given the current price, market conditions and momentum of this stock? Do you have a price target or idea of what the 1 year consensus is?
Q: Hi Peter,
I have a small position in Biosyent. Admittedly it had a very good run in 2014, but has gone a bit silent in recent months despite strong numbers. Would you see this as normal consolidation or are there other issues at play. I'm a bit underwater and would appreciate your thoughts on whether to hold or to move on.
Thanks
I have a small position in Biosyent. Admittedly it had a very good run in 2014, but has gone a bit silent in recent months despite strong numbers. Would you see this as normal consolidation or are there other issues at play. I'm a bit underwater and would appreciate your thoughts on whether to hold or to move on.
Thanks
Q: I would appreciate your assessment of Biosyent's earnings release issued this morning. Thank you, Peter
Q: RX-X Any idea why BioSyent is going up like a rocket these days? Could it fall as quickly or is there something there to sustain the rise? Appreciate your expertise.
Q: Could you please comment on Biosyent's (RX) earnings released this morning? They look outstanding to me but I do not know what the market is expecting. And in the "outstanding" category 51 is the best!
Q: i would appreciate any information or thoughts on rx-t
Q: Hi 5i team,
I currently hold Cipher, but was thinking about switching into Biosyent. Although Biosyent has a lower market cap, it also has more diversification in its operations and better stock momentum. What are your thoughts on this switch?
Thanks as always,
I currently hold Cipher, but was thinking about switching into Biosyent. Although Biosyent has a lower market cap, it also has more diversification in its operations and better stock momentum. What are your thoughts on this switch?
Thanks as always,
Q: GOOD AFTERNOON. HAVE YOU ANY IDEA WHAT IS DRIVING RX -BIOSYNT - LATELY. STOCK IS UP A LOT. THANKS
Q: rx on the venture, do you know anything about this company. dave
Q: BioSyent (RX-V) still speculative and risky or is it turning out to be a possible longer term play? It has a real nice steady climbing curve.
Q: Your thoughts on RX-V please. Many thanks
Q: Since late last year rx biosynt has found its 52 week high again.. with the new products and recent new highs I purchased some shares at it broke out.. how do you feel about this one
Q: Peter,
it's been a wonderful 12 months for Biosyent Symbol Rx, what a chart. From an all time high of $1.40 recently, following their most recent quarterly report, it has pulled back to close to $1, would you see this as a buying opportunity,
regards Lawrence
it's been a wonderful 12 months for Biosyent Symbol Rx, what a chart. From an all time high of $1.40 recently, following their most recent quarterly report, it has pulled back to close to $1, would you see this as a buying opportunity,
regards Lawrence